TME Pharma Valuation Multiples

TME Pharma Overview

About TME Pharma

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

Founded

2015

HQ

Employees

12

Website

tmepharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: —

EBITDA: ($5M)

EV

$7M

Valuation Multiples

Multiples.vc

Start free trial

TME Pharma Financials

TME Pharma reported last fiscal year revenue of — and negative EBITDA of ($5M).

In the same fiscal year, TME Pharma generated ($5M) in EBITDA losses and had net loss of ($7M).

TME Pharma P&L

In the most recent fiscal year, TME Pharma reported revenue of — and EBITDA of ($5M).

TME Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

TME Pharma Stock Performance

TME Pharma has current market cap of $7M, and enterprise value of $7M.

TME Pharma's stock price is $0.08.

TME Pharma Valuation Multiples

TME Pharma trades at (1.3x) EV/EBITDA.

TME Pharma Financial Valuation Multiples

As of March 30, 2026, TME Pharma has market cap of $7M and EV of $7M.

Equity research analysts estimate TME Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

TME Pharma has a P/E ratio of (1.2x).

TME Pharma Margins & Growth Rates

TME Pharma's revenue in the last fiscal year grew by —.

TME Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

TME Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

TME Pharma M&A Activity

TME Pharma acquired XXX companies to date.

Last acquisition by TME Pharma was on XXXXXXXX, XXXXX. TME Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

TME Pharma Investment Activity

TME Pharma invested in XXX companies to date.

TME Pharma made its latest investment on XXXXXXXX, XXXXX. TME Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).